Sangamo Therapeutics Inc. (SGMO)

11.47
0.18 1.60
NASDAQ : Health Technology
Prev Close 11.29
Open 11.35
Day Low/High 11.10 / 11.39
52 Wk Low/High 9.00 / 27.50
Volume 594.17K
Avg Volume 1.84M
Exchange NASDAQ
Shares Outstanding 102.09M
Market Cap 1.16B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Brinks, Medtronic, Fiat Chrysler: 'Mad Money' Lightning Round

Brinks, Medtronic, Fiat Chrysler: 'Mad Money' Lightning Round

Jim Cramer weighs in on Brinks, Sangamo Biosciences, Medtronic, Fiat Chrysler, GW Pharmaceuticals, EPR Properties.

SGMO: Insiders Vs. Shorts

SGMO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 12/14/2018 settlement date, and Sangamo Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 11.12 "days to cover" versus the median component at 4.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of SGMO August 16th Options Trading

First Week Of SGMO August 16th Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sangamo Announces Completion Of TxCell Acquisition

Sangamo Announces Completion Of TxCell Acquisition

RICHMOND, Calif. and VALBONNE, France, Dec.

Sangamo Therapeutics Becomes Oversold (SGMO)

Sangamo Therapeutics Becomes Oversold (SGMO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Sangamo Therapeutics Reports Third Quarter 2018 Financial Results

Sangamo Therapeutics Reports Third Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

SGMO: Insiders Vs. Shorts

SGMO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/28/2018 settlement date, and Sangamo Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.54 "days to cover" versus the median component at 4.65. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Sangamo And TxCell Announce The Completion Of The Acquisition By Sangamo Of Majority Of TxCell Ordinary Shares

Sangamo And TxCell Announce The Completion Of The Acquisition By Sangamo Of Majority Of TxCell Ordinary Shares

Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy

First Week Of January 2021 Options Trading For Sangamo Therapeutics (SGMO)

First Week Of January 2021 Options Trading For Sangamo Therapeutics (SGMO)

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Despite $5.1 billion deal for Costa, I'm not slurping any KO up.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

Salesforce Remains a 'Go to' Name for Big Cap Momentum Players

Salesforce Remains a 'Go to' Name for Big Cap Momentum Players

I expect CRM to regain its footing quickly and challenge highs again soon.

HPE: Surpassing Expectations, Raising Guidance Incrementally

HPE: Surpassing Expectations, Raising Guidance Incrementally

If estimates continue to come up there will be institutional interest in the stock.

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Apple in particular is helping the bullish cause.

Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment

TheStreet Quant Rating: D+ (Sell)